R. Kelly

R. Hales, D. Ettinger, L. Yarmus, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors

C. Lin, R. Hales, D. Ettinger, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dabrafenib and trametinib for the treatment of non-small cell lung cancer

R. Kelly, 2018, Expert review of anticancer therapy.

Cancer Therapy: Clinical A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

S. Steinberg, T. Fojo, S. Bates, 2011 .

Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett's Esophagus to Invasive Esophageal Adenocarcinoma

C. Chung, S. Meltzer, M. Zahurak, 2019, Annals of surgery.

Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer.

N. Kemeny, G. Leonard, R. Kelly, 2005, Clinical colorectal cancer.

Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer

W. Weichert, F. Lordick, Z. Szabo, 2022, Journal of Cancer Research and Clinical Oncology.

Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report

G. Giaccone, D. Ettinger, C. Rudin, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic.

Thomas J. Smith, G. Rosner, P. Forde, 2015, Journal of oncology practice.

Scientific Advances in Lung Cancer 2015

Kenneth E. Rosenzweig, Hisao Asamura, Annette McWilliams, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.

G. Giaccone, E. Szabo, J. Trepel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer

F. Shepherd, A. Krivoshik, L. Horn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Vaccines for lung cancer

R. Kelly, 2012 .

Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.

G. Giaccone, C. Carter, R. Kelly, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928)

M. Socinski, E. Smit, Gregory Riely, 2014 .

Aff ordable cancer care 1 Delivering maximum clinical benefi t at an aff ordable price: engaging stakeholders in cancer care

Thomas J. Smith, R. Kelly, Teresa Smith, 2014 .

Serial Endoscopic Evaluation of Esophageal Disease in a Cancer Model: A Paradigm Shift for Esophageal Adenocarcinoma (EAC) Drug Discovery and Development

D. Matsui, R. Kelly, B. Jobe, 2017, Cancer investigation.

Bone marrow-derived macrophages from AβPP/PS1 mice are sensitized to the effects of inflammatory stimuli.

M. Lynch, Raasay S. Jones, R. Kelly, 2015, Journal of Alzheimer's disease : JAD.

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Y. Bang, M. Rebelatto, H. Lenz, 2019, Clinical Cancer Research.

Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy

E. Montgomery, I. Pastan, P. Illei, 2016, Applied immunohistochemistry & molecular morphology : AIMM.

Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice

M. Lynch, Raasay S. Jones, C. McDonald, 2014, Neurobiology of Aging.

Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.

C. Lin, R. Hales, D. Ettinger, 2019, Clinical lung cancer.

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.

C. Lin, D. Ettinger, L. Yarmus, 2019, The Journal of clinical investigation.

Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease.

Michael J Kerin, Nicola Miller, H. Heneghan, 2010, The oncologist.

Classical activation of microglia in CD200-deficient mice is a consequence of blood brain barrier permeability and infiltration of peripheral cells

M. Lynch, A. Lyons, C. McDonald, 2013, Brain, Behavior, and Immunity.

Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19

S. Anderson, E. Priest, Tainya C. Clarke, 2022, PloS one.

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

J. Ajani, T. Zander, A. Lièvre, 2021, The New England journal of medicine.

Target Inhibition in Antiangiogenic Therapy A Wide Spectrum of Selectivity and Specificity

R. Kelly, O. Rixe, C. Darnell, 2010, Cancer journal.

Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events.

Ami A. Shah, J. Albayda, C. Bingham, 2018, Rheumatology.

Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.

H. Groen, M. Socinski, E. Smit, 2017 .

Thymoma-associated paraneoplastic polymyositis.

G. Giaccone, S. Browne, A. Rajan, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thymomas and Thymic Tumors

A. Marchevsky, R. Kelly, 2017 .

Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer

W. Weichert, F. Lordick, Z. Szabo, 2022, Journal of Cancer Research and Clinical Oncology.

Single agent anti PD-1 inhibitors in esophageal cancer-a first step in a new therapeutic direction.

R. Kelly, E. Walsh, 2018, Journal of thoracic disease.

Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness Analysis.

Thomas J. Smith, R. Kelly, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Texas Immuno-Oncology Biorepository, a statewide biospecimen collection and clinical informatics system to enable longitudinal tumor and immune profiling

A. Baker, M. Berens, K. V. Van Keuren-Jensen, 2022, Baylor University Medical Center Proceedings.

A blood-based circulating microbial metagenomic panel for early diagnosis and prognosis of oesophageal adenocarcinoma

Patrick L. Wagner, R. Kelly, B. Jobe, 2022, British Journal of Cancer.

The role of talactoferrin alfa in the treatment of non-small cell lung cancer

G. Giaccone, R. Kelly, 2010, Expert opinion on biological therapy.

Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma

D. Sahu, A. Goel, R. Kelly, 2022, Biomarker Research.

FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-Oncology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC.

J. Ajani, G. Ku, T. George, 2017 .

Reducing the cost of cancer care: how to bend the curve downward.

Thomas J. Smith, B. Hillner, R. Kelly, 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

High yield reproducible rat model recapitulating human Barrett’s carcinogenesis

D. Matsui, R. Kelly, B. Jobe, 2017, World journal of gastroenterology.

CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease

D. Matsui, R. Kelly, R. Biederman, 2017, Oncotarget.

Cancer of the esophagus

Stephen C. Yang, L. Kleinberg, R. Kelly, 1998 .

Emerging Multimodality Approaches to Treat Localized Esophageal Cancer.

R. Kelly, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Axitinib (AG-013736).

R. Kelly, O. Rixe, 2010, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

The emerging role of immunotherapy for esophageal cancer.

R. Kelly, 2019, Current opinion in gastroenterology.

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.

J. Lacy, S. Park, Y. Bang, 2020, The Lancet. Oncology.

Scientific Advances in Thoracic Oncology 2016.

H. Groen, C. Rudin, R. Rami-Porta, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model

R. Landreneau, D. Matsui, R. Kelly, 2017, Annals of surgery.

HER2 mutations in non-small-cell lung cancer can be continually targeted.

G. Giaccone, C. Carter, R. Kelly, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

State of the art management of metastatic gastroesophageal cancer.

R. Kelly, D. Lynch, A. Murphy, 2015, Annals of translational medicine.

From Molecular Classification to Targeted Therapeutics: The Changing Face of Systemic Therapy in Metastatic Gastroesophageal Cancer

R. Kelly, A. Murphy, 2015, Gastroenterology research and practice.

Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.

P. Forde, R. Kelly, 2013, The oncologist.

Transforming growth factor-beta: A target for cancer therapy

R. Kelly, J. Morris, J. Morris, 2010, Journal of immunotoxicology.

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Udayan Guha, Seth M Steinberg, Keith Killian, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.

G. Giaccone, S. Steinberg, Helen X. Chen, 2014, The Lancet. Oncology.

Thymic malignancies: from clinical management to targeted therapies.

Yi-Song Wang, G. Giaccone, A. Rajan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma.

R. Kelly, B. Jobe, A. Zaidi, 2019, Journal of Clinical Oncology.

New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer

P. Forde, J. Brahmer, R. Kelly, 2014, Clinical Cancer Research.

Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine

E. Szabo, R. Kelly, E. Sharon, 2010, Head & neck oncology.

Small-molecule inhibitors of the human epidermal receptor family

G. Giaccone, C. Carter, R. Kelly, 2009, Expert opinion on investigational drugs.

Thymoma versus thymic carcinoma: differences in biology impacting treatment.

R. Kelly, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Reply to C.G. Azzoli et al and C. Chouaid et al.

Thomas J. Smith, B. Hillner, R. Kelly, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: who is going to blink at the cost?

Thomas J. Smith, B. Hillner, R. Kelly, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma

Toby C. Cornish, N. Ahuja, J. Taube, 2016, Gut.

The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation

J. Silverman, D. Matsui, David H. Wang, 2017, Annals of surgery.

The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer.

R. Kelly, A. Murphy, 2017, Hematology/oncology clinics of North America.

Immunotherapy in Upper GI Malignancies

R. Kelly, A. Murphy, 2015, Current Treatment Options in Oncology.

Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model

Soyoung Lee, A. Goel, R. Kelly, 2021, Oncotarget.

Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma

A. Goel, R. Kelly, B. Jobe, 2019, Oncotarget.

Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma

S. Badylak, J. Silverman, D. Matsui, 2016, Oncotarget.

A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

Robert W. Robey, Aradhana M. Venkatesan, Frank M. Balis, 2010, Clinical Cancer Research.

Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor

R. Kelly, O. Rixe, 2009, Targeted Oncology.

Renal toxicity of targeted therapies

R. Kelly, O. Rixe, B. Billemont, 2009, Targeted Oncology.

Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib

G. Giaccone, S. Steinberg, P. Choyke, 2011, Clinical Cancer Research.

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

G. Giaccone, W. Zein, B. Houk, 2011, Clinical Cancer Research.

New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice

P. Forde, J. Brahmer, R. Kelly, 2014, Clinical Cancer Research.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Chao Huang, M. Socinski, J. Neal, 2018, Lung cancer.

Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011.

Thomas J. Smith, D. Geynisman, Y. Shih, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

Ira Pastan, I. Pastan, R. Kelly, 2012, Molecular Cancer Therapeutics.

Glial Activation in AβPP/PS1 Mice is Associated with Infiltration of IFNγ-Producing Cells.

M. Lynch, A. Lyons, Raasay S. Jones, 2013, Journal of Alzheimer's disease : JAD.

A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.

G. Giaccone, J. Doroshow, R. Parchment, 2010 .

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.

Marilyn M. Li, T. Burns, S. Ramalingam, 2019, Lung cancer.

Multisystem immune-related adverse events from anti-PD-1/PD-L1 in patients with lung cancer: Incidence, clinical patterns, management, and outcomes.

D. Ettinger, J. Feliciano, J. Naidoo, 2019, Journal of Clinical Oncology.

Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis.

H. Groen, D. Planchard, J. Mazières, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

H. Risch, E. Lerma, M. Zervos, 2020, The American Journal of Medicine.

Metastatic phyllodes tumor causing small-bowel obstruction.

R. McDermott, N. Swan, R. Kelly, 2009, Clinical Breast Cancer.

Recent advances in immune-based approaches for the treatment of esophagogastric cancer

R. Kelly, A. Duffy, C. Weadick, 2021, Expert opinion on emerging drugs.

Infected radial artery pseudoaneurysm: a rare entity

R. Kelly, R. Weedle, S. Siddiqui, 2021 .

Multicenter phase 2: Capecitabine (CAP) + oxaliplatin (OX) + bevacizumab (BEV) + trastuzumab (TRAS) for patients (pts) with metastatic esophagogastric cancer (MEGCA).

J. Meyerhardt, C. Fuchs, P. Enzinger, 2015 .

Chemotherapeutic and Targeted Strategies for Locally Advanced and Metastatic Esophageal Cancer

P. Forde, R. Kelly, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma

R. Kelly, A. Duffy, E. Lynch, 2023, Pharmaceuticals.

Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.

G. Giaccone, G. Oxnard, A. Krivoshik, 2016 .

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer

G. Rosner, D. Ettinger, E. Gabrielson, 2018, The oncologist.

LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study

J. Ajani, T. Zander, A. Lièvre, 2020 .

Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).

J. Lacy, S. Park, Y. Bang, 2018 .

Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC.

G. Giaccone, G. Oxnard, A. Krivoshik, 2015 .

CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.

Y. Doki, B. Melichar, S. Clarke, 2017 .

Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer.

R. Kelly, H. Tan, P. Abraham, 2020, Future oncology.

Immunotherapy for Esophageal and Gastric Cancer.

R. Kelly, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer.

R. Hales, V. Velculescu, V. Anagnostou, 2019, Journal of Clinical Oncology.

Magnitude and duration of immune checkpoint up-regulation and changes in the immune microenvironment post chemo-radiation (CRT) in esophageal cancer.

J. Silverman, D. Matsui, David H. Wang, 2017 .

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

G. Giaccone, G. Oxnard, A. Krivoshik, 2017, Clinical Cancer Research.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer

G. Ku, M. Fakih, S. Krishnamurthi, 2023, Journal for ImmunoTherapy of Cancer.

Complications and Economic Burden Associated With Obtaining Tissue for Diagnosis and Molecular Analysis in Patients With Non-Small-Cell Lung Cancer in the United States.

J. Rigas, S. Karve, R. Kelly, 2019, Journal of oncology practice.

Challenges, Perceptions, and Readiness of Oncology Clinicians for the MACRA Quality Payment Program

C. Nabhan, B. Feinberg, R. Kelly, 2017, JAMA oncology.

A phase I study of paclitaxel, carboplatin, and YM155 (survivin suppressor) in subjects with solid tumors.

G. Giaccone, A. Rajan, R. Kelly, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the insulin-like growth factor-1 receptor (IGF-1R) antibody cixutumumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC).

G. Giaccone, Helen X. Chen, A. Rajan, 2010 .

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma

K. Steele, M. Rebelatto, K. Almhanna, 2015, Journal of Immunotherapy for Cancer.

1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577

J. Ajani, T. Zander, A. Lièvre, 2021, Annals of Oncology.

Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.

J. Ajani, T. Zander, A. Lièvre, 2021 .

Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).

S. Park, Y. Bang, Yoon-Koo Kang, 2018 .

A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.

T. Burns, S. Ramalingam, D. Gerber, 2014 .

Serial Endoscopic Evaluation of Esophageal Disease in a Cancer Model: A Paradigm Shift for Esophageal Adenocarcinoma (EAC) Drug Discovery and Development

D. Matsui, R. Kelly, B. Jobe, 2018, Cancer investigation.

Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

I. Pastan, R. Kelly, R. Hassan, 2012, Molecular Cancer Therapeutics.

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.

C. Lin, D. Ettinger, L. Yarmus, 2019, The Journal of clinical investigation.

Complications and Economic Burden Associated with Obtaining Tissue for Diagnosis and Molecular Analysis in Patients with Non-Small Cell Lung Cancer (NSCLC) in the US (Preprint)

J. Rigas, S. Karve, R. Kelly, 2018 .

Mapping fireline intensity and flame height of prescribed gorse wildland fires

R. Kelly, M. Katurji, Shana E. Gross, 2023, Fire Safety Journal.

Lung Cancer Vaccines

G. Giaccone, R. Kelly, 2011, Cancer journal.

Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.

G. Giaccone, J. Gulley, R. Kelly, 2010, Clinical lung cancer.

Emerging Multimodality Approaches to Treat Localized Esophageal Cancer.

R. Kelly, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Brave new world-new and emerging treatments for gastric cancer.

R. Kelly, E. Lynch, Austin G. Duffy, 2023, Chinese clinical oncology.

Role of Immunotherapy in Gastroesophageal Cancers—Advances, Challenges and Future Strategies

R. Kelly, E. Lynch, Austin G. Duffy, 2023, Cancers.

Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies.

G. Giaccone, J. Trepel, A. Rajan, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer

P. Forde, J. Brahmer, R. Kelly, 2014, Clinical Cancer Research.

Thymoma-associated paraneoplastic polymyositis.

G. Giaccone, S. Browne, A. Rajan, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer of the esophagus

Stephen C. Yang, L. Kleinberg, R. Kelly, 1998 .

Systemic treatment of advanced thymic malignancies.

R. Kelly, 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Mesothelin expression in patients as a novel target in gastric cancer.

E. Montgomery, I. Pastan, P. Illei, 2014 .

Criteria of evidence to move potential chemopreventive agents into late phase clinical trials.

E. Szabo, R. Kelly, A. López-Chávez, 2011, Current drug targets.

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

V. Anagnostou, R. Kelly, K. Marrone, 2024, Nature medicine.

MA 09.08 Receipt of Chest Radiation and Immune-Related Pneumonitis in Patients with NSCLC Treated with Anti-PD-1/PD-L1

R. Hales, D. Ettinger, J. Hayman, 2017 .

Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

Lauren L. Ritterhouse, J. Meyerhardt, D. Rubinson, 2024, Nature communications.